跳至主要内容
临床试验/NCT05256498
NCT05256498撤回不适用

Electrophysiological Studies of the Human Pudendal Nerve Using Short-duration Extracorporeal Stimulation

Amber Therapeutics Ltd0 个研究点开始时间: 2022年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
Intraoperative pelvic floor electromyography (EMG)

研究概览

简要总结

AURA 1 (Augmenting Urinary Reflex Activity: study 1) is a study that evaluates the electrophysiological responses of pudendal nerve stimulation using short-duration extracorporeal stimulation

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients aged ≥ 18 years with urological indications (OAB, UUI, UFS, retention syndromes and pain)
  • Meeting criteria for routine SNM (primary or revision surgery) at the discretion of their normal care urologist.
  • Ability and willingness to give informed consent
  • Willingness to stay overnight in hospital after SNM procedure (as per routine care)

排除标准

  • Patient is pregnant, breastfeeding, or plans to become pregnant during the course of the study (pregnancy tests provided in schedule) [this is an exclusion for SNM in any case]
  • Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints
  • Any psychiatric or personality disorder at the discretion of the study physician
  • Any neurological condition that may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease; clinically significant peripheral neuropathy, or complete spinal cord injury)
  • Patient has uncontrolled type I or type II diabetes as defined by their routine care clinician or diabetes with peripheral nerve involvement
  • Patient has history of other non-pelvic neoplasia within 5 years prior to enrolment, except for a cancer that was determined to be local occurrence only, such as basal cell carcinoma, or is receiving or planning to receive anti-cancer or anti-angiogenic drugs
  • Patient has proven major autoimmune disease, e.g. scleroderma or immunodeficiency (including use of biologic immunomodulatory drugs at time of procedure)
  • Patient is not suitable for the study as determined by their routine care physician for any other reason
  • Patient is enrolled in another interventional study excepting observational studies, e.g. SNM registries or in relation to disease (see below)
  • Patient participation in vigorous sporting activities where these cannot be restricted for a period of 24h while the extracorporeal lead is in situ.
  • Specific urological
  • As per routine clinical SNM criteria (see: https://www.nice.org.uk/guidance/ipg6434)
  • Specific technical
  • Patient is significantly obese (defined as BMI ≥ 35) so as to limit electrode lead placement using standard approaches
  • Skin, orthopaedic or neurological anatomical limitations that could prevent successful placement of the electrode lead
  • Subject with a documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone

结局指标

主要结局

Intraoperative pelvic floor electromyography (EMG)

时间窗: 24 Hours

Intra-operative measurements of amplitude of pelvic floor EMG upon pudendal nerve stimulation

次要结局

  • Pelvic floor electromyography (EMG)(24 Hours)
  • Technical outcomes(24 Hours)

研究者

发起方
Amber Therapeutics Ltd
申办方类型
Industry
责任方
Sponsor

相似试验